Trial ChiCTR2100041705, ChiCTR2100041706
Publication Feng Y, medRxiv, 2021
Primary outcome on the report: 1. Seroconversion rates (geometric mean titer (GMT) ≥ 16) and GMT of neutralizing antibody to live SARS-CoV-2 at day 28 after the last dose; 2. Occurrence of adverse reactions within 7 days after the first and second vaccinations

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.